

POLY/EP 98/08554



The
Patent
Office



EP 98/08554

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP9 1RH

5

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

A handwritten signature in black ink.

Dated 11 January 1999

00-20-10 H

H0100-99
The Patent Office



8661 NAV 22

The Patent Office
23JAN98 E332816-13 D02898
-P01/7700 25.00 - 9801420
Cardin Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference	F 7418 (V)		
2. Patent application number <i>(The Patent Office will fill in this part)</i>	22 JAN 1998	9801420.2	
3. Full name, address and postcode of the or of each applicant <i>(underline all surnames)</i>	UNILEVER PLC UNILEVER HOUSE, BLACKFRIARS LONDON, EC4P 4BQ <i>1428002</i> UNITED KINGDOM		
Patents ADP number <i>(if you know it)</i>			
If the applicant is a corporate body, give the country/state of its incorporation			
4. Title of the invention	FROZEN FOOD PRODUCT		
5. Name of your agent <i>(if you have one)</i>	Susan Edith KIRSCH PATENT DIVISION, UNILEVER PLC COLWORTH HOUSE, SHARNBROOK BEDFORD, MK44 1LQ <i>5991054602</i>		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and <i>(if you know it)</i> the or each application number	Country	Priority application number <i>(if you know it)</i>	Date of filing <i>(day / month / year)</i>
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing <i>(day/month/year)</i>
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? <i>(Answer 'Yes' if:</i>	YES <i>a) any applicant named in part 3 is not an inventor, or</i> <i>b) there is an inventor who is not named as an applicant, or</i> <i>c) any named applicant is a corporate body.</i> <i>See note (d))</i>		

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description	13
Claim(s)	1
Abstract	1
Drawing(s)	

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

Date: 20 January 1998

Dilshad RAJAN, Authorised Signatory

12. Name and daytime telephone number of person to contact in the United Kingdom

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Frozen Food product5 Technical Field of the Invention

The invention relates to anti-freeze proteins (AFPs) and frozen food product containing AFPs.

10 Background to the Invention

Anti-freeze proteins (AFPs) have been suggested for improving the freezing tolerance of foodstuffs.

15 For the purpose of the invention, the term AFP has the meaning as well-known in the art, namely those proteins which exhibit the activity of inhibit the growth of ice crystals. See for example US 5,118,792.

20 WO 90/13571 discloses antifreeze peptides produced chemically or by recombinant DNA techniques. The AFPs can suitably be used in food-products.

WO 92/22581 discloses AFPs from plants which can be used
25 for controlling ice crystal shape in ice-cream. This document also describes a process for extracting a polypeptide composition from extracellular spaces of plants by infiltrating leaves with an extraction medium without rupturing the plants.

WO 94/03617 discloses the production of AFPs from yeast and their possible use in ice-cream. WO 96/11586 describes fish AFPs produced by microbes.

5 Several literature places also mention the isolation and/or use of plant proteins for cryoprotection. Cryoprotective proteins have a function in the protection of plant membranes against frost damage. These proteins, however, do not possess recrystallisation inhibition properties and
10 are, therefore, not embraced within the terms AFPs.

Hincha in Journal of Plant Physiology, 1992, 140, 236-240 describes the isolation of cryoprotective proteins from cabbage. Volger in Biochimica et Biophysica Acta, 412
15 (1975), 335-349 describes the isolation of cryoprotective leaf proteins from spinach. Boothe in Plant Physiol (1995), 108: 759-803 describes the isolation of proteins from Brassica napus. Again, these proteins are believed to be cryoprotective proteins rather than AFPs. Neven in Plant
20 Molecular Biology 21: 291-305, 1993 describes the DNA characterisation of a spinach cryoprotective protein.
Salzman in Abstracts and Reviews of the 18th Annual Meeting of the ASEV/Eastern Section in Am. J. Enol. Vitic., Vol.
25 No. 4, 1993 describes the presence of boiling-stable polypeptides in buds of Vitis. Although the proteins are analogous to fish antifreeze peptides, they are cryoprotective proteins and not AFPs. Lin in Biochemical and Biophysical Research Communication, Vol. 183, No. 3, 1992, pages 1103-1108 and in Lin, Plant Physiology (1992)
30 99, 519-525 describes the 15 kDa cryoprotective polypeptide from Arabidopsis Hakaire. Houde in The Plant Journal (1995) 8 (4), 583-593 mentions cryoprotective proteins from wheat.

Up till now, however the use of AFPs has not been applied to commercially available food products. One reason for this are the high costs and complicated process for 5 obtaining AFPs. Another reason is that the AFPs which until now have been suggested for use in frozen food products cannot be incorporated in the standard formulation mix, because they tend to destabilise during processing especially during the pasteurisation step. This 10 destabilisation is believed to be caused by the denaturation of the AFPs; this is a well-known effect commonly observed for peptides and proteins.

In our non pre-published patent application: PCT/EP97/3637 15 it has been described that particularly good AFPs can be isolated from natural sources such as Lichen.

Applicants have now been able to determine the partial amino acid sequence of a particularly active AFP from 20 Lichen.

Accordingly the invention relates to an AFP which can be derived from Lichen, said AFP having an apparent molecular weight of about 24 kDa and an amino acid sequence from the 25 N-terminus of:

A-P-A-W-M-D-A-E-S-F-G-A-I-A-H-G-G-L

Also embraced in the scope of our invention are proteins having a sequence which has a high degree of similarity 30 with the above sequence. For the purpose of the invention all RI active proteins having an amino acid sequence of at least 80% overlap with the above sequence are also embraced

BIO-TECHNIK

in the scope of the invention. More preferred is an overlap of at least 90%, most preferred more than 95%, e.g. those amino acid sequences which differ none or only one or two amino acids with the above sequence.

5

Also embraced within the scope of the present invention are modified versions of the above described proteins whereby said modification does not materially affect the ice recrystallisation inhibition properties, such as 10 glycosylated versions thereof.

For the purpose of the invention the term about 24 kDa molecular weight means any molecular weight from 20 to 28 kDa as measured on SDS-PAGE using standard reference 15 markers, more preferably the molecular weight is from 22 to 26 kDa.

The advantageous AFP of the present invention can be derived from Lichen.

20

Also embraced within the scope of the present invention are anti-freeze proteins which although originally derived from Lichen are produced by other methods, for example by genetic modification techniques whereby for example 25 microorganisms or plants are genetically modified to produce the above described proteins. These proteins are also embraced within the term "can be derived from Lichen".

30 Also embraced within the scope of the present are nucleic acid sequences which are capable to encode the above described AFPs.

Vectors containing a nucleic acid sequence capable of encoding the AFP of the invention are also embraced within the scope of the invention.

5

Based on the above information it is also possible to genetically modify other natural sources such that they produce the advantageous AFP as identified here-above.

10

Applicants also have found that AFPs of the above sequence have improved ice-recrystallidation inhibition properties. A suitable test for determining the ice recrystallisation inhibition properties is described in the examples and 15 involves the quick freezing to -40°C followed by storage for one hour at -6°C. Preferably AFPs in accordance to the invention provide a ice particle size following an ice recrystallisation inhibition assay -as described in the examples- of 15 µm or less, more preferred from 5 to 15 µm.

20

The AFP of the invention can conveniently be used in food products, preferably in food products which are frozen or intended to be frozen. Especially preferred is the use of AFPs in products which are heated e.g. by pasteurisation or 25 sterilisation prior to freezing. Especially preferred is the use in frozen confectionery products.

Examples of such food products are: frozen confectionery mixes such as ice-cream mixes and water-ice mixes which are 30 intended to be pasteurised prior to freezing. Such mixes are usually stored at ambient temperature. Suitable product forms are for example: a powder mix which is packed for

example in a bag or in sachets. Said mix being capable of forming the basis of the frozen food product e.g. after addition of water and optionally other ingredients and - optional- aeration.

5

Another example of a suitable mix could be a liquid mix (optionally aerated) which, if necessary after addition of further components and optional further aeration can be frozen.

10

The clear advantage of the above mentioned mixes is that the presence of the AFP ingredient makes that the mixes can be frozen under quiescent conditions, for example in a shop or home freezer without the formation of unacceptable ice crystal shapes and hence with a texture different to products normally obtained via quiescent freezing.

Very conveniently these mixes are packed in closed containers (e.g. cartons, bags, boxes, plastic containers etc). For single portions the pack size will generally be from 10 to 1000 g. For multiple portions pack sizes of up to 500 kg may be suitable. Generally the pack size will be from 10 g to 5000 g.

25 As indicated above the preferred products wherein the AFPs are used are frozen confectionery product such as ice-cream or water-ice. Preferably the level of AFPs is from 0.00001 to 0.5 wt% based on the final product. If dry-mixes or concentrates are used, the concentration may be higher in 30 order to ensure that the level in the final frozen product is within the above ranges.

For the purpose of the invention the term frozen confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas 5 and frozen fruit purees. For some applications the use in fermented food products is less preferred.

Preferably a the level of solids in the frozen confection (e.g. sugar, fat, flavouring etc) is more than 4 wt%, for 10 example more than 30 wt%, more preferred from 40 to 70wt%.

Frozen confectionery products according to the invention can be produced by any method suitable for the production of frozen confectionery. Especially preferably however all 15 the ingredients of the formulation are fully mixed before pasteurisation and before the freezing process starts. The freezing process may advantageously involve a hardening step, for example to a temperature of -30 Fahrenheit or lower.

Example I

The ice recrystallisation inhibition properties of the AFPs can be determined as follows:

5 A sample of an AFP containing product was adjusted to a sucrose level of 30 wt% (If the starting level of the sample was more than 30% this was done by dilution, if the starting level was lower sucrose was added to the 30% level).

10

A 3 μL drop of the sample was placed on a 22 mm coverslip. A 16 mm diameter cover-slip was then placed on top and a 200 g weight was placed on the sample to ensure a uniform slide thickness. The edges of the coverslip were sealed 15 with clear nail varnish.

The slide was placed on a Linkham THM 600 temperature controlled microscope stage. The stage was cooled rapidly (50 $^{\circ}\text{C}$ per minute) to -40°C to produce a large population 20 of small crystals. The stage temperature was then raised rapidly (50 $^{\circ}\text{C}$ per minute) to -6°C and held at this temperature.

The ice-phase was observed at -6°C using a Leica 25 Aristoplan microscope. Polarised light conditions in conjunction with a lambda plate were used to enhance the contrast of the ice crystals. The state of the ice phase (size of ice crystals) was recorded by 35 mm photomicrography at T=0 and T=1 hour. The ice-crystal size 30 (length) was determined by drawing around the perimeter of the crystals. The maximum length for each individual ice crystal of a batch of ice cream was imported into a

spreadsheet where analysis of the data set was carried out to find the mean, and standard deviation.

Generally this test can be applied to any suitable 5 composition comprising AFP and water. Generally the level of AFP in such a test composition is not very critical and can for example be from 0.0001 to 0.5 wt%, more preferred 0.0005 to 0.1 wt%, most preferred 0.001 to 0.05 wt%, for example 0.01 wt%

10

Any suitable composition comprising AFP and water can be used to carry out the test. Generally, however, it will not be necessary to obtain the AFP in purified form. For practical applications normally it would suffice to prepare 15 a liquid extract or juice of natural material, wherein this extract or juice can then be tested.

08-20-10 H

10

Example II

9.5 g Umbilicaria antarctica collected during Spring 1996
5 from the Antarctic and stored at -20 C was homogenised in
liquid nitrogen in a mortar and pestle to a fine powder.
This powder was transferred to a fresh mortar and pestle
held at room temperature. Following the addition of 10 ml
0.2 M Tris HCl containing 10 mM EDTA the powder was further
10 ground in the mortar and pestle and the homogenate filtered
through 2 layers of muslin. The retentate was replaced in
the mortar and pestle and a further 10 ml buffer added and
the retentate ground further. This material was filtered as
above and the filtrate pooled with filtrate from the first
15 homogenisation step. The filtrate was centrifuged at 30,000
g for 15 minutes and the supernatant collected and frozen
in aliquots.

0.15 g NH₄SO₄ was dissolved in 1ml supernatant and the
20 solution incubated for 30 minutes at 4 C. After
centrifugation at 30,000 g for 10 minutes 0.3 g NH₄SO₄ was
dissolved in the supernatant from this step and the
solution incubated at 4 C for 30 minutes. The solution was
centrifuged at 30,000 g for 10 minutes and the supernatant
25 discarded. The pellet was resuspended in 0.2 ml water and
serial dilutions of this solution and the original extract
prepared in 30 % (w/w) sucrose in water for semi-
quantitative splat analysis. Splat activity could be
detected (by the above method) in the original extract to a
30 dilution of more than 200 fold and in the resuspended
pellet to a dilution of 800 fold indicating that more than

half of the total splat activity present in the original extract had been harvested in the NH₄SO₄ pellet.

200 microlitre 0.1 M TrisHCl pH 7.5 was added to the 5 resuspended pellet and the solution concentrated in a 10 kDa cut-off microcon (Amicon) to 150 microlitre. 100 microlitre of this solution was applied to a Q-Sepharose column pre-equilibrated in 50 mM Tris Hcl pH 7.5 using a SMART chromatographysystem (Pharmacia) at a flow rate of 10 100 microlitre per minute and 100 microlitre fractions collected. Following 800 microlitre was in 50 mM Tris Hcl pH 7.5, a 0-0.5 M NaCl gradient was applied to the column over 1.5 ml and the eluate monitored at 280 nm. Following 50 fold dilution in 30 w/w % sucrose, fractions were tested 15 for splat activity as in example I. Activity was found to correlate with a peak of OD 280 which eluted at approximately 0.1 M NaCl which was mainly collected in fraction 14.

20 40 microlitre fraction 14 was applied to a Superdex 75 gel permeation column pre-equilibrated in 50 mM Tris HCl pH 7.5 at a flow rate of 40 microlitre per minute usinga SMART chromatography system (Pharmacia). The eluate was monitored at OD 280 and OD 215 and the 80 microlitre fractions were 25 collected from 0.6 ml after sample application, 50 microlitre fractions between 1.1 and 1.6 ml and 100 microlitre fractions between 1.6 and 3 ml. 1 microlitre from each fraction was diluted 25 times in 30 w/w% sucrose and assayed for splat activity. Activity was found to 30 correlate with a peak of OD280 and OD215 which eluted with a retention of 1.2 ml in fractions 9 and 10. The Superdex column was calibrated by determination of the retention

RESULTS

12

volume (V_e) of standard protein molecular weight markers (Sigma) BSA (66 kDa, 1.58 ml) and the void volume (V_0) determined as 0.91 ml by application of the blue dextran. A standard curve of $\log_{10} Mr$ against V_e/V_0 was plotted and 5 the apparent molecular weight of the OD 280 peak correlating with the lichen splat activity determined as 30 kDa.

32 microlitre from fractions 9 and 10 eluting from the 10 Superdex column were pooled and concentrated to 10 microlitre in a 10 kDa cut-off microcom (Amicon) and 3.5 microlitre 4x SDS-PAGE was added to 10 microlitre fractions 9 and 10 eluting from the Superdex column and to fractions 12-16 eluting from the Q-sepharose column. Following 15 heating 95 C for five minutes and centrifugation at 10,000 g for 3 minutes 10 microlitres of each sample was loaded into weels ina 4% stacking gel and polypeptides separated by electrophoresis through a 12% 0.75 mm thick SDS-PAGE mini-gel (bio-rad). Following electrophoresis the gel was 20 stained and fixed in Coomassie Brilliant Blue and destained in methanol:acetic acid:water (1:4:5) w/w. This revealed a polypeptide of apparent Mr 24 kDa in the concentrated pooled fractions 9 amd 10 eluting from the Superdex xolumn. When the gel was silver stained using the Biorad silver 25 stain kit according to the manufacturers instructions, a polypeptide with the same apparent Mr was detectable in fraction 14 eluting from the Q-Sepharose column and in fractions 9 and 10 eluting from the Superdex column.

30 Following purification of further protein using essentially the same methodology as described above, the following N-

F

(V)

H 01.00.99

13

terminal amino-acid sequence was obtained from the 24 kDa polypeptide:

A-P-A-W-M-D-A-E-S-F-G-A-I-A-H-G-G-L

5

00-20-10 H

Claims

1. Anti-freeze protein which can be derived from Lichen, said protein having an apparent molecular weight of from 20 to 28 kDa and having an N-terminal amino acid sequence which shows at least 80% overlap with:
A-P-A-W-M-D-A-E-S-F-G-A-I-A-H-G-G-L
and modified versions and isoforms of this protein
2. Anti-freeze protein of claim 1, having a molecular weight of from 22 to 26 kDa.
3. Anti-freeze protein of claim 1, showing at least 90% overlap with the indicated sequence.
4. Anti-freeze protein of claim 3, showing 100% overlap.
5. Anti-freeze protein of claim 1, wherein the modification involves glycosylation.
6. Nucleic acid sequence encoding the anti-freeze protein of one or more of the preceding claims.
7. Food product comprising a anti-freeze protein according to claim 1.
8. Food product according to claim 7 being a frozen confectionery product.

H01-00-99

15

Abstract

Anti-freeze protein which can be derived from Lichen, said protein having an apparent molecular weight of from 20 to 28 kDa and having an N-terminal amino acid sequence which shows at least 80% overlap with:

A-P-A-W-M-D-A-E-S-F-G-A-I-A-H-G-G-L

and modified versions and isoforms of this protein

EE-50-10 H